Readjustment of the plan for the centre promoting the creation of an innovative medical industry in Tonomachi, Kawasaki
First written in FY2018-Q2. 6 of 12 entries say "Advanced", first in FY2018. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「Building A of the Cybernics Medical Innovation Base is operating in the Tonomachi International Strategic Zone in Kawasaki, promoting the systematization of cybernics therapies combining HAL with regenerative medicine and pharmaceuticals, as well as the development of technologies integrating medical and biotechnology with AI, robotics, and information technology. The company is advancing the move-in of life sciences companies, with business synergies anticipated, and collaboration with C-Startup partners in regenerative medicine and drug discovery.」
The company is reaffirming the operation of the base following the start of operations at Building A in Tonomachi and collaboration with life sciences companies and C-Startup partners. - FY2024-Q3RestatedAnnual report
「At the Tonomachi International Strategic Zone in Kawasaki, also known as King Skyfront, Building A of the Cybernics Medical Innovation Base, which promotes the development of new medical technologies combining cybernics therapies such as HAL® with regenerative medicine and drug discovery, was completed. Since January 2023, life sciences companies, including C-Startup partners in regenerative medicine and drug discovery, have been moving into the facility. The company will continue to select collaboration partners in stages, with business synergies anticipated.」
The company is reaffirming the occupancy of life sciences companies in Building A in Tonomachi and its policy of selecting collaboration partners in stages. - FY2024-Q2AdvancedAnnual report
「At the Tonomachi International Strategic Base in Kawasaki (King Skyfront), Cybernics Medical Innovation Base Building A, which promotes the development of new medical technologies, including HAL®-based cybernics treatment, regenerative medicine and drug discovery, was completed. Since January 2023, life sciences companies, including C-Startup partners in regenerative medicine and drug discovery, have been moving in, with 4 companies already occupying the facility and 2 companies having decided to move in. The company will continue to select collaboration partners in stages, anticipating business synergies.」
Building A in Tonomachi was completed, with 4 life sciences companies having moved in and 2 companies having decided to move in since January 2023. The company has stated its policy of selecting collaboration partners in stages going forward. - FY2023-Q3AdvancedAnnual report
「At the Tonomachi International Strategic Base in Kawasaki (King Skyfront), Cybernics Medical Innovation Base Building A, which promotes the development of new medical technologies, including HAL®-based cybernics treatment, regenerative medicine and drug discovery, was completed, and partner companies have been moving in since January 2023.」
Building A in Tonomachi was completed, and the company moved to the stage of partner companies beginning to move in from January 2023. - FY2023-Q2AdvancedAnnual report
「At the Tonomachi International Strategic Base in Kawasaki (King Skyfront), the main structure of Cybernics Medical Innovation Base Building A, which promotes clinical research into cybernics treatment such as HAL® as well as bioresearch including regenerative medicine and drug discovery, was completed in March 2022, and additional interior work is under way (occupancy scheduled to begin in January 2023).」
The main structure of Building A in Tonomachi was completed in March 2022, progressing to the stage of additional interior work and preparations for occupancy beginning in January 2023. - FY2023-Q1AdvancedAnnual report
「At the Tonomachi International Strategic Base in Kawasaki (King Skyfront), the main structure of Cybernics Medical Innovation Base Building A, which promotes clinical research into cybernics treatment such as HAL® as well as bioresearch including regenerative medicine and drug discovery, was completed in March 2022, and additional interior work is under way (scheduled to become operational during fiscal 2022).」
The main structure of Building A in Tonomachi, Kawasaki was completed in March 2022, progressing to the stage of additional interior work and preparations for becoming operational during fiscal 2022. - FY2022-Q1RestatedAnnual report
「At the Tonomachi International Strategic Base in Kawasaki (King Skyfront), construction of Cybernics Innovation Base Building A began in December 2020. The facility will promote bioresearch, including regenerative medicine and drug discovery, in addition to clinical research on HAL® and other technologies, and is scheduled for completion at the end of fiscal 2021.」
Following the start of construction on Building A at the Tonomachi base in December 2020, the company is reaffirming its scheduled completion at the end of fiscal 2021 as a base for promoting clinical research, regenerative medicine and drug discovery. - FY2021-Q3AdvancedAnnual report
「At the centre promoting the creation of an innovative medical industry in Tonomachi, Kawasaki (King Skyfront), construction of the tentatively named Cybernics Building A began in December 2020, with completion scheduled for February 2022.」
Cybernics Building A in Tonomachi, Kawasaki progressed to the stage of construction commencement and a stated completion schedule of February 2022. - FY2021-Q1ReframedAnnual report
「At the centre promoting the creation of an innovative medical industry in Tonomachi, Kawasaki (King Skyfront), construction of the tentatively named Cybernics Building A is scheduled for completion at the end of fiscal 2021.」
The Tonomachi base in Kawasaki, for which the plan had previously been readjusted and the description removed, was again explicitly presented as the construction plan for the tentatively named Cybernics Building A, with completion scheduled for the end of fiscal 2021. - FY2019DroppedAnnual report
「We continue to make capital expenditures aimed at strengthening administrative functions and enhancing research and development capabilities. Capital expenditures for the current consolidated fiscal year totaled ¥789 million, mainly consisting of partial payments toward the acquisition of land in Tsukuba, Ibaraki Prefecture.」
In this year's filing, the previous description of the readjustment of the plan for the Tonomachi base in Kawasaki is absent, and the main capital investment is described as the acquisition of land in Tsukuba. - FY2018AdvancedAnnual report
「We continue to make capital investments to strengthen management functions and enhance research and development capabilities. Total capital investment for the consolidated fiscal year was ¥1,126 million, mainly comprising expenditure at the Tonomachi International Strategic Base in Kawasaki, Kanagawa Prefecture, and partial payment for the acquisition of land in Tsukuba, Ibaraki Prefecture.」
The company is proceeding with capital investment, including expenditure at the Tonomachi International Strategic Base and the acquisition of land in Tsukuba, and continues to invest in developing its bases even after readjusting the plan. - FY2018-Q2First statedAnnual report
「With regard to the centre promoting the creation of an innovative medical industry in Tonomachi, Kawasaki (King Skyfront), we are readjusting the plan in light of rising construction costs ahead of the 2020 Tokyo Olympics.」
The company has disclosed for the first time as a standalone topic that it is readjusting the plan for the medical industry creation centre in Tonomachi, Kawasaki, in light of rising construction costs.